A Comparative Analysis of Remdesivir and Other Repurposed Antivirals Against SARS-CoV-2

Overview

Journal EMBO Mol Med

Specialty Molecular Biology

Date 2020 Oct 5

PMID 33015938

Citations 44

Authors

Alexander Simonis

Sebastian J Theobald

Gerd Fatkenheuer

Jan Rybniker

Jakob J Malin

Affiliations

Soon will be listed here.

Abstract

The ongoing SARS-CoV-2 pandemic stresses the need for effective antiviral drugs that can quickly be applied in order to reduce morbidity, mortality, and ideally viral transmission. By repurposing of broadly active antiviral drugs and compounds that are known to inhibit viral replication of related viruses, several advances could be made in the development of treatment strategies against COVID-19. The nucleoside analog remdesivir, which is known for its potent in vitro activity against Ebolavirus and other RNA viruses, was recently shown to reduce the time to recovery in patients with severe COVID-19. It is to date the only approved antiviral for treating COVID-19. Here, we provide a mechanism and evidence-based comparative review of remdesivir and other repurposed drugs with proven in vitro activity against SARS-CoV-2.

Citing Articles

Bovine Serum Albumin Nanoparticle-Mediated Delivery of Ribavirin and Mycophenolic Acid for Enhanced Antiviral Therapeutics.

Castaneda Catana M, Rivas Marquina A, Dodes Traian M, Carlucci M, Damonte E, Perez O Viruses. 2025; 17(2).

PMID: 40006893 PMC: 11860702. DOI: 10.3390/v17020138.

Recent Advances in the Synthesis of Acyclic Nucleosides and Their Therapeutic Applications.

Kumar S, Arora A, Chaudhary R, Kumar R, Len C, Mukherjee M Top Curr Chem (Cham). 2024; 382(4):34.

PMID: 39441318 DOI: 10.1007/s41061-024-00476-7.

Further preclinical characterization of molnupiravir against SARS-CoV-2: Antiviral activity determinants and viral genome alteration patterns.

Petit P, Touret F, Driouich J, Cochin M, Luciani L, Bernadin O Heliyon. 2024; 10(10):e30862.

PMID: 38803975 PMC: 11128822. DOI: 10.1016/j.heliyon.2024.e30862.

Developing nucleoside tailoring strategies against SARS-CoV-2 via ribonuclease targeting chimera.

Min Y, Xiong W, Shen W, Liu X, Qi Q, Zhang Y Sci Adv. 2024; 10(15):eadl4393.

PMID: 38598625 PMC: 11006213. DOI: 10.1126/sciadv.adl4393.

potently inhibits the activity of SARS-CoV-2 3CL protease.

Hao Z, Liu Y, Guan W, Pan J, Li M, Wu J Biochem Biophys Rep. 2024; 37:101626.

PMID: 38371528 PMC: 10873874. DOI: 10.1016/j.bbrep.2023.101626.

References

Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J . Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering (Beijing). 2020; 6(10):1192-1198. PMC: 7185795. DOI: 10.1016/j.eng.2020.03.007. View

Paton N, Aboulhab J, Karim F . Hydroxychloroquine, hydroxycarbamide, and didanosine as economic treatment for HIV-1. Lancet. 2002; 359(9318):1667-8. DOI: 10.1016/S0140-6736(02)08557-4. View

Simonis A, Theobald S, Fatkenheuer G, Rybniker J, Malin J . A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2. EMBO Mol Med. 2020; 13(1):e13105. PMC: 7646058. DOI: 10.15252/emmm.202013105. View

Bosch B, van der Zee R, de Haan C, Rottier P . The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J Virol. 2003; 77(16):8801-11. PMC: 167208. DOI: 10.1128/jvi.77.16.8801-8811.2003. View

Leneva I, Russell R, Boriskin Y, Hay A . Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol. Antiviral Res. 2008; 81(2):132-40. DOI: 10.1016/j.antiviral.2008.10.009. View

Wrapp D, Wang N, Corbett K, Goldsmith J, Hsieh C, Abiona O . Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367(6483):1260-1263. PMC: 7164637. DOI: 10.1126/science.abb2507. View

Zhang C, Shi L, Wang F . Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020; 5(5):428-430. PMC: 7129165. DOI: 10.1016/S2468-1253(20)30057-1. View

van der Lugt J, Lange J, Avihingsanon A, Ananworanich J, Sealoo S, Burger D . Plasma concentrations of generic lopinavir/ritonavir in HIV type-1-infected individuals. Antivir Ther. 2009; 14(7):1001-4. DOI: 10.3851/IMP1410. View

Huang D, Yu H, Wang T, Yang H, Yao R, Liang Z . Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. J Med Virol. 2020; 93(1):481-490. PMC: 7361300. DOI: 10.1002/jmv.26256. View

10.

Horby P, Lim W, Emberson J, Mafham M, Bell J, Linsell L . Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2020; 384(8):693-704. PMC: 7383595. DOI: 10.1056/NEJMoa2021436. View

11.

LAAKSONEN A, Koskiahde V, JUVA K . Dosage of antimalarial drugs for children with juvenile rheumatoid arthritis and systemic lupus erythematosus. A clinical study with determination of serum concentrations of chloroquine and hydroxychloroquine. Scand J Rheumatol. 1974; 3(2):103-8. DOI: 10.3109/03009747409115809. View

12.

Naarding M, Baan E, Pollakis G, Paxton W . Effect of chloroquine on reducing HIV-1 replication in vitro and the DC-SIGN mediated transfer of virus to CD4+ T-lymphocytes. Retrovirology. 2007; 4:6. PMC: 1796897. DOI: 10.1186/1742-4690-4-6. View

13.

Ksiazek T, Erdman D, Goldsmith C, Zaki S, Peret T, Emery S . A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003; 348(20):1953-66. DOI: 10.1056/NEJMoa030781. View

14.

Choy K, Wong A, Kaewpreedee P, Sia S, Chen D, Hui K . Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res. 2020; 178:104786. PMC: 7127386. DOI: 10.1016/j.antiviral.2020.104786. View

15.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G . A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020; 382(19):1787-1799. PMC: 7121492. DOI: 10.1056/NEJMoa2001282. View

16.

Spinner C, Gottlieb R, Criner G, Lopez J, Cattelan A, Soriano Viladomiu A . Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2020; 324(11):1048-1057. PMC: 7442954. DOI: 10.1001/jama.2020.16349. View

17.

Jefferson T, Jones M, Doshi P, Del Mar C, Hama R, Thompson M . Neuraminidase inhibitors for preventing and treating influenza in adults and children. Cochrane Database Syst Rev. 2014; (4):CD008965. PMC: 6464969. DOI: 10.1002/14651858.CD008965.pub4. View

18.

Shannon A, Selisko B, Le N, Huchting J, Touret F, Piorkowski G . Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis. Nat Commun. 2020; 11(1):4682. PMC: 7499305. DOI: 10.1038/s41467-020-18463-z. View

19.

Kamp T, Hamdan M, January C . Chloroquine or Hydroxychloroquine for COVID-19: Is Cardiotoxicity a Concern?. J Am Heart Assoc. 2020; 9(12):e016887. PMC: 7429067. DOI: 10.1161/JAHA.120.016887. View

20.

Varghese F, Thaa B, Amrun S, Simarmata D, Rausalu K, Nyman T . The Antiviral Alkaloid Berberine Reduces Chikungunya Virus-Induced Mitogen-Activated Protein Kinase Signaling. J Virol. 2016; 90(21):9743-9757. PMC: 5068526. DOI: 10.1128/JVI.01382-16. View